Similarly, in lung cancer, PRMT5 inhibition disrupts the HIF-1α/VEGFR/AKT/eNOS axis and downstream nitric oxide production, thereby impairing angiogenesis and EMT [367]. Here, PRMT5 is linked to lung cancer.